Study S002581

Transformative Research in Diabetic Nephropathy 2.0: A Proof of Principle Study of SGLT2 Inhibitors (TRIDENT 2.0)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07444203
Acronym: TRIDENT 2
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 200
Start: 2025-11-12
Primary completion: 2027-05-30
Lead sponsor: University of Pennsylvania
Conditions: Diabetic Nephropathies; Kidney Diseases; Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: DRUG:Sodium-glucose cotransporter 2 inhibitors (SGLT2i); DRUG:Renin-angiotensin-aldosterone system blockade; DRUG:Glucagon-like peptide-1 receptor agonists (GLP 1 RA); DRUG:Mineralocorticoid Receptor Antagonists(MRAs)
Results posted: FALSE

Registered primary outcomes

Change in Kidney Tissue molecular fingerprint [Baseline enrollment to 18 months.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.